Pay in 4 interest-free payments of $7.45 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favourable benefit-safety profile
PT-141 (bremelanotide) selectively targets MC3R and MC4R, activating central nervous system pathways for sexual function without triggering melanogenesis
Trends May Be More Informative Than One Reading Comparing results obtained under similar conditions can help show whether: Kidney function remains stable Electrolytes are changing A1C and glucose are improving Triglycerides and cholesterol are responding Iron or vitamin status is declining Liver-related markers are improving or worsening Test Conditions Matter Results may vary because of: Fasting or recent meals Hydration Vomiting or diarrhea Recent strenuous exercise Alcohol intake Acute illness or inflammation Supplements, including biotin Other prescription medications Menstruation or pregnancy Age, sex, muscle mass, and recent weight change Differences in laboratory methods Do not stop, reduce, or increase a GLP-1 medication or another prescription drug based solely on direct-access laboratory results
Targeted Benefits: Supports detoxification, reduces brain fog, protects against oxidative stress, and promotes radiant skinall in a portable, easy-to-use spray
